
Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.


Ayal Aizer, MD, MHS, discusses the unmet needs in treating patients with brain metastases.

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical implications for community oncology.

Dong Chen, MD, PhD, discusses how AI has changed the landscape for genomic testing and patient management.

Prof Martin Dreyling discusses the unmet needs in MCL and the potential next lines of research on the BTK inhibitor acalabrutinib.

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.

Manmeet Ahluwalia, MD, MBA, FASCO, shares a message during Brain Cancer Awareness Month.

Anuradha Krishnamurthy, MBBS, discusses the exciting frontier of tumor-infiltrating lymphocyte therapy in melanoma and other disease states.

Statin use in CLL/SLL patients showed improved survival regardless of treatment, suggesting repurposing potential for this accessible drug.

Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.

Neel Shah, MD, our first 2025 Oncology Icon, reflected on his journey from academic medicine to community oncology.

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study that supports it.

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing cancer research directly impacts patient care.

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients with mantle cell lymphoma.

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Anuradha Krishnamurthy, MBBS, discusses what physicians and patients must aware of regarding the safety of TIL therapy in melanoma.

Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.

Deepak Bhamidipati, MD, discusses a review conducted to investigate how the design of early-phase clinical trials has evolved.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.


C. Ola Landgren, MD, PhD, discusses the feedback he received on minimal residual disease at this year’s Miami Myeloma MRD Meeting in April.

Anuradha Krishnamurthy, MBBS, provides backgrounds on TILs and discusses their critical role in the advanced melanoma treatment landscape.

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.

Deepak Bhamidipati, MD, discusses the impact of the FDA's Project Optimus on early-phase drug development protocols.